<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02631954</url>
  </required_header>
  <id_info>
    <org_study_id>151HPS14014</org_study_id>
    <nct_id>NCT02631954</nct_id>
  </id_info>
  <brief_title>Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection
      200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in
      Healthy Volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To healthy volunteers subjects of twenty four(24), following treatments are administered
      dosing in each period injected wash-out period is a minimum of 7days. Treatment A(Test Drug):
      Vorico Injection 200mg(Voriconazole) for Single Dose Treatment B(Reference Drug): Vfend® IV
      200mg for Single Dose Pharmacokinetic blood samples are collected up to 24hrs.

      Safety and pharmacokinetic are assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Voriconazole</measure>
    <time_frame>0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs</time_frame>
    <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt of Voriconazole</measure>
    <time_frame>0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs</time_frame>
    <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax of Voriconazole</measure>
    <time_frame>0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs</time_frame>
    <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Voriconazole</measure>
    <time_frame>0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs</time_frame>
    <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt/AUCinf</measure>
    <time_frame>0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs</time_frame>
    <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel (Elemination Rate Constant)</measure>
    <time_frame>0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs</time_frame>
    <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs</time_frame>
    <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Aspergillus Infections</condition>
  <condition>Candida Infections</condition>
  <condition>Fungal Infections</condition>
  <arm_group>
    <arm_group_label>TR Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test drug: Vorico Injection 200mg(Voriconazole) Wash out: 7 days Reference drug: Vfend® IV 200mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reference drug: Vfend® IV 200mg Wash out: 7 days Test drug: Vorico Injection 200mg(Voriconazole)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorico Injection 200mg(Voriconazole)</intervention_name>
    <description>Vorico Injection 200mg(Voriconazole) to administered intravenously once</description>
    <arm_group_label>RT group</arm_group_label>
    <arm_group_label>TR Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vfend®(Voriconazole) IV 200mg</intervention_name>
    <description>Vfend®(Voriconazole) IV 200mg to administered intravenously once</description>
    <arm_group_label>RT group</arm_group_label>
    <arm_group_label>TR Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A healthy person whose age is in between 19 to 55 during the screening tests

          2. Whose weight is more than 55 kg, BMI is over 18.5 and under 30.0 during the screening
             test. (BMI (kg/m2) = weight (kg) / {height (m)}2)

          3. Who is completely informed and understand about this clinical trial, voluntarily
             participating it, and signed to follow the given instructions

          4. Who is proven to fit into the clinical trial following by physical examination, ECG
             (electrocardiogram), clinical laboratory test, medical examination

          5. Who agreed to do birth control during testing

               -  A male who did not have vasectomy has to follow the clinically proven
                  contraceptive methods* listed under, and who agreed not to donate sperm during
                  the test

                  * Clinically proven contraceptive method: intrauterine device (ex. Lippes Loop,
                  Minera), chemical contraceptive (spermicides) for use with physical contraceptive
                  method (males or females), contraceptive implants (ex. Implanon), tubal ligation
                  or laparoscopy (common methods of tubal ligation)

               -  A woman of childbearing age who agreed on constant use of a medically disproven
                  Dual Protection method** and spermicides except hormonal contraceptive, and who
                  also agreed not to breastfeed.

                    -  A Dual Protection method: use of condoms, the Intrauterine Contraceptive
                       Device, the diaphragm, the cervical cap, in the case where a sexual partner
                       had vasectomy over 3 months ago (from the date of initial screening) or a
                       sexual partner had been medically diagnosed sterile.

        Exclusion Criteria:

          1. A person who has a history of clinically significant cardiovascular, respiratory,
             liver, kidney, endocrine system, immune system, urinary system diseases, blood-tumor
             diseases, mental illness.

          2. Who has a history of hypersensitivity reactions to antifungal drugs including
             voriconazole or similar series or other excipient ingredients (aspirin, antibiotics,
             etc.)

          3. Who has genetics issues on galactose intolerance, Lapp lactose deficiency, or
             glucose-galactose malabsorption

          4. Who has a history of gastrointestinal disease (Crohn's disease, ulcer, acute or
             chronic pancreatitis, etc.) or gastrointestinal surgery (other than simple
             appendectomy and herniotomy)

          5. A person whose electrocardiogram value includes QTc &gt; 440 msec, PR &lt; 110 msec or PR &gt;
             200 msec, QRS &lt; 60 msec or QRS &gt; 110 msec after screening, or who show clinically
             significant opinion.

          6. Who falls under the following results

               1. AST, ALT are exceeded over 1.5x the upper limit of the normal range

               2. Total bilirubin is exceeded over 1.5x the upper limit of the normal range

          7. Who shows the vital sign values of more than 140 mmHg or less than 90 mmHg in systolic
             pressure or more than 100 mmHg or less than 60 mmHg in diastolic blood pressure

          8. Who has history of drug abuses or shows a positive result in the urinary drug screen

          9. Who took any prescribed drugs, medicinal plants within the 2 weeks before the first
             day of dosing or takes any over-the-counter drugs or vitamin supplements within 1 week
             (but, if other conditions are met, they can still participate in the clinical test
             through the researcher's judgment)

         10. Who took other investigational drugs or bioequivalence drugs within 3 months before
             the first day of dosing

         11. Who participated in whole blood donation within 2 months before the first of dosing,
             or platelet donations within 1 months. Who received blood a month before the first day
             of dosing

         12. Who constantly drinks alcohol (over 21 units/week, 1 unit = 10 g of pure alcohol) or
             cannot stop drinking alcohol during the clinical test.

         13. Who smokes more than 10 cigarettes per day, or who cannot quit smoking when
             hospitalized

         14. Who absorb caffeinated drinks (coffee, tea (black or green tea), soda, coffee flavored
             milk, energy drinks, etc.) or cannot stop absorbing them 24 hours before
             hospitalization until discharging

         15. Who takes drug metabolism drug like barbital drugs which inhibit or activate the
             metabolism or drugs, or who takes one of the following drugs: St. John's Wort,
             rifabutin, rifampicin, carbamazepine, phenobarbital, high-dose of ritonavir,
             terfenadine, astemizole, cisapride, pimozide, quinidine, sirolimus, ergot, alkaloid
             (ergotamine, dihydroergotamine), efavirenz

         16. Who was having foods (especially grapefruit or products contain grapefruit) that can
             influence the drug absorption, distribution, metabolism, and excretion within 7 days
             from the first day of dosage

         17. A woman who is pregnant, shows positive result in serum/urine test, or who is
             breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>December 13, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <results_first_submitted>February 12, 2020</results_first_submitted>
  <results_first_submitted_qc>March 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 18, 2020</results_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Subjects who passed the screening were randomized using IWRS before conducting the clinical trail.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TR Group</title>
          <description>Test drug: Vorico Injection 200mg(Voriconazole) Wash out: 7 days Reference drug: Vfend® IV 200mg
Vorico Injection 200mg(Voriconazole): Vorico Injection 200mg(Voriconazole) to administered intravenously once
Vfend®(Voriconazole) IV 200mg: Vfend®(Voriconazole) IV 200mg to administered intravenously once</description>
        </group>
        <group group_id="P2">
          <title>RT Group</title>
          <description>Reference drug: Vfend® IV 200mg Wash out: 7 days Test drug: Vorico Injection 200mg(Voriconazole)
Vorico Injection 200mg(Voriconazole): Vorico Injection 200mg(Voriconazole) to administered intravenously once
Vfend®(Voriconazole) IV 200mg: Vfend®(Voriconazole) IV 200mg to administered intravenously once</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>24 subejcts were used for baseline analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>TR Group</title>
          <description>Test drug: Vorico Injection 200mg(Voriconazole) Wash out: 7 days Reference drug: Vfend® IV 200mg
Vorico Injection 200mg(Voriconazole): Vorico Injection 200mg(Voriconazole) to administered intravenously once
Vfend®(Voriconazole) IV 200mg: Vfend®(Voriconazole) IV 200mg to administered intravenously once</description>
        </group>
        <group group_id="B2">
          <title>RT Group</title>
          <description>Reference drug: Vfend® IV 200mg Wash out: 7 days Test drug: Vorico Injection 200mg(Voriconazole)
Vorico Injection 200mg(Voriconazole): Vorico Injection 200mg(Voriconazole) to administered intravenously once
Vfend®(Voriconazole) IV 200mg: Vfend®(Voriconazole) IV 200mg to administered intravenously once</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>healthy subjects aged 19 to 55 yesars were selected.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Voriconazole</title>
        <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
        <time_frame>0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reference</title>
            <description>Reference: Vfend® IV 200mg drug
RT group: Vfend®(Voriconazole) IV 200mg to administered intravenously once at Period I
TR group: Vfend®(Voriconazole) IV 200mg to administered intravenously once at Period II</description>
          </group>
          <group group_id="O2">
            <title>Test</title>
            <description>Test: Vorico Injection 200mg(Voriconazole) drug
RT group: Vorico Injection 200mg(Voriconazole) to administered intravenously once at Period II
TR group: Vorico Injection 200mg(Voriconazole) to administered intravenously once at Period I</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Voriconazole</title>
          <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2433.7" spread="2456.9"/>
                    <measurement group_id="O2" value="1997.0" spread="406.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCt of Voriconazole</title>
        <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
        <time_frame>0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reference</title>
            <description>Reference: Vfend® IV 200mg drug
RT group: Vfend®(Voriconazole) IV 200mg to administered intravenously once at Period I
TR group: Vfend®(Voriconazole) IV 200mg to administered intravenously once at Period II</description>
          </group>
          <group group_id="O2">
            <title>Test</title>
            <description>Test: Vorico Injection 200mg(Voriconazole) drug
RT group: Vorico Injection 200mg(Voriconazole) to administered intravenously once at Period II
TR group: Vorico Injection 200mg(Voriconazole) to administered intravenously once at Period I</description>
          </group>
        </group_list>
        <measure>
          <title>AUCt of Voriconazole</title>
          <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6966.17" spread="2856.10"/>
                    <measurement group_id="O2" value="7469.78" spread="3125.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of Voriconazole</title>
        <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
        <time_frame>0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reference</title>
            <description>Reference: Vfend® IV 200mg drug
RT group: Vfend®(Voriconazole) IV 200mg to administered intravenously once at Period I
TR group: Vfend®(Voriconazole) IV 200mg to administered intravenously once at Period II</description>
          </group>
          <group group_id="O2">
            <title>Test</title>
            <description>Test: Vorico Injection 200mg(Voriconazole) drug
RT group: Vorico Injection 200mg(Voriconazole) to administered intravenously once at Period II
TR group: Vorico Injection 200mg(Voriconazole) to administered intravenously once at Period I</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Voriconazole</title>
          <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="0.03"/>
                    <measurement group_id="O2" value="1.58" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCinf of Voriconazole</title>
        <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
        <time_frame>0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reference</title>
            <description>Reference: Vfend® IV 200mg drug
RT group: Vfend®(Voriconazole) IV 200mg to administered intravenously once at Period I
TR group: Vfend®(Voriconazole) IV 200mg to administered intravenously once at Period II</description>
          </group>
          <group group_id="O2">
            <title>Test</title>
            <description>Test: Vorico Injection 200mg(Voriconazole) drug
RT group: Vorico Injection 200mg(Voriconazole) to administered intravenously once at Period II
TR group: Vorico Injection 200mg(Voriconazole) to administered intravenously once at Period I</description>
          </group>
        </group_list>
        <measure>
          <title>AUCinf of Voriconazole</title>
          <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8159.24" spread="4905.05"/>
                    <measurement group_id="O2" value="8631.50" spread="4401.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCt/AUCinf</title>
        <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
        <time_frame>0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reference</title>
            <description>Reference: Vfend® IV 200mg drug
RT group: Vfend®(Voriconazole) IV 200mg to administered intravenously once at Period I
TR group: Vfend®(Voriconazole) IV 200mg to administered intravenously once at Period II</description>
          </group>
          <group group_id="O2">
            <title>Test</title>
            <description>Test: Vorico Injection 200mg(Voriconazole) drug
RT group: Vorico Injection 200mg(Voriconazole) to administered intravenously once at Period II
TR group: Vorico Injection 200mg(Voriconazole) to administered intravenously once at Period I</description>
          </group>
        </group_list>
        <measure>
          <title>AUCt/AUCinf</title>
          <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="0.10"/>
                    <measurement group_id="O2" value="0.90" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kel (Elemination Rate Constant)</title>
        <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
        <time_frame>0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reference</title>
            <description>Reference: Vfend® IV 200mg drug
RT group: Vfend®(Voriconazole) IV 200mg to administered intravenously once at Period I
TR group: Vfend®(Voriconazole) IV 200mg to administered intravenously once at Period II</description>
          </group>
          <group group_id="O2">
            <title>Test</title>
            <description>Test: Vorico Injection 200mg(Voriconazole) drug
RT group: Vorico Injection 200mg(Voriconazole) to administered intravenously once at Period II
TR group: Vorico Injection 200mg(Voriconazole) to administered intravenously once at Period I</description>
          </group>
        </group_list>
        <measure>
          <title>Kel (Elemination Rate Constant)</title>
          <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
          <units>1/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.03"/>
                    <measurement group_id="O2" value="0.10" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2</title>
        <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
        <time_frame>0 , 0.5, 1, 1.25, 1.5, 1.58, 1.67, 1.83, 2, 2.5, 3, 4, 6, 8, 12, 24 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reference</title>
            <description>Reference: Vfend® IV 200mg drug
RT group: Vfend®(Voriconazole) IV 200mg to administered intravenously once at Period I
TR group: Vfend®(Voriconazole) IV 200mg to administered intravenously once at Period II</description>
          </group>
          <group group_id="O2">
            <title>Test</title>
            <description>Test: Vorico Injection 200mg(Voriconazole) drug
RT group: Vorico Injection 200mg(Voriconazole) to administered intravenously once at Period II
TR group: Vorico Injection 200mg(Voriconazole) to administered intravenously once at Period I</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2</title>
          <description>The blood sampleing coleected from the subjects was analyzed and result was obtained.</description>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.42" spread="4.61"/>
                    <measurement group_id="O2" value="7.98" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 months</time_frame>
      <desc>There was no serious AE. A total of 58 AEs out of 24 subjects who took IP more than at least one time, were observed.
All of the AEs were mild and recovered.</desc>
      <group_list>
        <group group_id="E1">
          <title>Reference</title>
          <description>Reference: Vfend® IV 200mg drug
RT group: Vfend®(Voriconazole) IV 200mg to administered intravenously once at Period I
TR group: Vfend®(Voriconazole) IV 200mg to administered intravenously once at Period II</description>
        </group>
        <group group_id="E2">
          <title>Test</title>
          <description>Test: Vorico Injection 200mg(Voriconazole) drug
RT group: Vorico Injection 200mg(Voriconazole) to administered intravenously once at Period II
TR group: Vorico Injection 200mg(Voriconazole) to administered intravenously once at Period I</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>photophobia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>colour blindness acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>visual impariment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>urine oxalate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>white blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sang-Heon Cho, Ph.D.</name_or_title>
      <organization>INHA UNIVERSITY HOSPITAL</organization>
      <phone>82-32-890-1122</phone>
      <email>shcho123@inha.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

